LBPH News and Press, Longboard Pharmaceuticals Inc. From 08/09/21

Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021 Initiated a number of IND-enabling preclinical studies for LP143 and LP659...

Gainers: Allied Healthcare Products (AHPI) +107%, SCWorx (WORX) +32%, Longboard Pharmaceuticals (LBPH) +18%, Dynatronics (DYNT) +14%, Shineco (TYHT) +13%.Losers: Meridian Bioscience (VIVO) -18%, Aridis Pharmaceuticals (ARDS) -17%, Simulat...

Longboard Pharmaceuticals (LBPH): Q1 GAAP EPS of -$0.84 beats by $0.29.Cash and cash equivalents balance of $120.9M.Press Release For further details see: Longboard Pharmaceuticals EPS beats by $0.29

Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 Successfully completed an upsized initial public offering (IPO) raising approximately $...

Following yesterday's announcement that the FDA issued a complete response letter for Nuplazid (pimavanserin) for a label extension, Mizuho analyst Vamil Divan has downgraded Acadia (ACAD) shares to neutral and lowered his price target to $25 from $37.He says the company is unlikely to win FD...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The second quarter is off to a blazing start with the S&P 500 Index pushing above 4,000 on the heels of President Bi...